Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients

Liu, Can; Wu, Weihong; Shang, Hongyan; Lin, Shaochong; Xun, Zhen; Huang, Er; Lin, Jinpiao; Yang, Bin; Ou, Qishui

doi:10.1016/j.cca.2018.02.015

Cited by 13 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, serum preS1 levels were significantly higher in patients with high grading of liver inflammatory activity as determined by liver biopsy. This result is consistent with previous reports in which LHBs were found to be higher in HBeAg‐positive CHB hepatitis and LHBs and MHBs levels were significantly lower in the inactive HBV carrier phase 6,8 . PreS is a highly immunogenic region of HBV and harbours many epitopes for B and T lymphocytes, 21,22 suggesting that abundant LHBs and MHBs might be associated with a greater immune response.…”

Section: Discussionsupporting

confidence: 93%

“…Recently, it was shown that the composition of hepatitis B surface antigen (HBsAg) changes significantly across different stages of HBV infection and that LHBs quantification could be a novel tool for identifying inactive HBV carrier stages 6,7 . Moreover, it was reported that the composition of HBsAg provides a better prediction of response to antiviral therapy such as pegylated interferon and nucleos(t)ide analogue (NA), and reduction of LHBs ratio during the NA treatment was associated with subsequent HBsAg loss in patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) 8,9 . However, the effect of preS1 values on CHB pathogenesis, such as hepatitis, liver fibrosis and hepatocarcinogenesis are not well known.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

Nishida

Imamura

Teraoka

et al. 2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

While the preS1 region of the large hepatitis B surface protein plays an essential role in hepatitis B virus (HBV) infection, the effect of preS1 on liver fibrosis and hepatocarcinogenesis in chronic hepatitis B (CHB) patients is not well known. In this study, we measured serum preS1 levels by chemiluminescent immunoassay technology in 690 CHB patients and evaluated the correlation between serum preS1 levels and HBV, liver function markers and liver inflammation, fibrosis assessed by histological findings. Predictive factors for hepatocellular carcinoma (HCC) development in patients who had no previous history of HCC at the time of preS1 level measurement were also analysed. Median hepatitis B surface antigen (HBsAg) and preS1 levels were 3.08 log IU/mL and 98 ng/mL, respectively. PreS1 values were significantly correlated with serum HBsAg (p <0.001), hepatitis B core‐related antigen (HBcrAg) (p <0.001) and HBV DNA levels (p <0.01). PreS1 values were also significantly correlated with serum alanine aminotransferase levels (p <0.001) and were significantly higher in patients who had higher grading of liver inflammatory activity (p <0.05). HBsAg level was correlated, but preS1/HBsAg ratio reflected liver fibrosis staging more directly than HBsAg alone. Multivariate analysis identified age ≥53 years (hazard ratio [HR], 18.360 for <53 years; p = 0.021) and preS1/HBsAg ratio ≥0.12 (HR, 6.205 for <0.12; p = 0.040) as significant and independent factors for HCC development in CHB patients. The preS1/HBsAg ratio directly reflects liver fibrosis, and the ratio might be a predictive marker for HCC development in CHB patients.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

Nishida

Imamura

Teraoka

et al. 2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…Most researches on HBsAg focused on the function of the small surface protein of HBsAg. PreS antigen (preS1Ag+preS2Ag) is the N-terminal extension of small surface protein, and the preS antigen, as well as middle and large surface proteins, have gained widespread attention in recent studies on the role of oncogenic risk factors [6], identification of inactive HBV carriers [10], prognosis of therapeutic response [12], and prediction value of HBV infection phases and virological response [37].…”

Section: Discussionmentioning

confidence: 99%

A Rapid Immunochromatographic Method Based on a Secondary Antibody-Labelled Magnetic Nanoprobe for the Detection of Hepatitis B preS2 Surface Antigen

Cai

Yan

Zhu³

et al. 2020

Biosensors

View full text Add to dashboard Cite

Hepatitis B is a globally prevalent viral infectious disease caused by the hepatitis B virus (HBV). In this study, an immunochromatographic assay (ICA) for the rapid detection of hepatitis B preS2 antigen (preS2Ag) was established. The magnetic nanoparticles (MNPs) indirectly labelled with goat anti-mouse (GAM) secondary antibody were applied as a nanoprobe for free preS2 antibody (preS2Ab) capturing and signal amplification. By employing sample pre-incubation processing as well, preS2Ag-preS2Ab was sufficiently caught by the GAM-MNPs probe in 5 min. A qualitative sensitivity of 625 ng/mL was obtained by naked-eye observation within 15–20 min. A standard curve (0–5000 ng/mL) was established, with a quantitative limit of detection (LOD) of 3.6 ng/mL, based on the stability and penetrability of the magnetic signal characteristics. The proposed method for preS2Ag was rapid (~25 min, cf. ELISA ~4 h) and had a good accuracy, which was verified using an ELISA kit (relative error < 15%). Large equipment and skilled technicians were not required. The sensitivity and specificity of the developed GAM-MNPs-ICA method were 93.3% and 90% in clinical serum samples (n = 25), respectively. A good detection consistency (84%) was observed between the developed ICA method and 2 types of commercial ELISA kits, indicating that the GAM-MNPs-ICA has a potential application in large-scale screening for and point-of-care diagnosis of hepatitis B or other infectious diseases.

show abstract

“…The ideal factors would be assessed before treatment to identify CHB patients that were not likely to respond to PEG-IFN-a therapy. We previously reported that polymorphisms of CYP27B1 were associated with PEG-IFN-a therapeutic efficacy in HBeAg-positive patients [27] and baseline serum HBV large surface protein (HBV-LP) level can be used for predicting virological response to PEG-IFNa in CHB patients [28]. Nevertheless, these indicators have not been commonly detected in clinic.…”

Section: Discussionmentioning

confidence: 99%

Association of Serum Total Cholesterol with Pegylated Interferon-α Treatment in HBeAg-Positive Chronic Hepatitis B Patients

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Recent studies suggest that serum lipids are associated with pegylated interferon-alpha (PEG-IFN-a) treatment response in chronic hepatitis C patients. However, the role of serum lipids in influencing the outcome of HBV treatment is not well understood. This study aims to investigate the association of serum lipids with the response to interferon-alpha treatment for chronic hepatitis B (CHB) patients. Methods: We dynamically measured 11 clinical serum lipid parameters of 119 hepatitis B e antigen (HBeAg)positive CHB patients, including 53 patients who achieved sustained response (SR) and 66 patients who achieved non-response (NR) induced by PEG-IFN-a treatment for 48 weeks. Results: The dynamic analysis showed that the baseline serum total cholesterol (TCHO) level was higher in the NR group than that in the SR group (P=0.004). Moreover, the correlation analysis demonstrated a significant positive correlation between TCHO and hepatitis B surface antigen (HBsAg) at baseline (P=0.009). In addition, CHB patients with high baseline TCHO levels exhibited higher HBV DNA, HBsAg, HBeAg and hepatitis B e antibody (HBeAb) levels during early treatment periods (weeks 0, 4, 12 and 24) than those with the low TCHO levels. Furthermore, the logistic regression analysis identified that baseline serum TCHO was a risk factor for NR achievement (OR=4.94; P=0.047). Conclusions: Our results indicated that serum TCHO was associated with PEG-IFN-a therapeutic response in HBeAg-positive CHB patients which suggested that serum TCHO could be useful as an auxiliary clinical factor to predict poor efficacy of PEG-IFN-a therapy.

show abstract

Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients

Cited by 13 publications

References 22 publications

Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

A Rapid Immunochromatographic Method Based on a Secondary Antibody-Labelled Magnetic Nanoprobe for the Detection of Hepatitis B preS2 Surface Antigen

Association of Serum Total Cholesterol with Pegylated Interferon-α Treatment in HBeAg-Positive Chronic Hepatitis B Patients

Contact Info

Product

Resources

About